Psilocybin Articles Archives

A High THC Dose Felt Like Psilocybin. The Study Had Four People

A Johns Hopkins pilot reported 25 mg of THC produced a psilocybin-like experience. It enrolled four participants and was funded by a cannabis foundation.

The Case That Psychedelics Sometimes Make Thinking Less Flexible

Cognitive flexibility is the standard explanation for how psychedelics work. A new review argues the acute effect may sometimes run the other way.

New Mexico Just Opened Its First Psilocybin Permits. The One Clinicians Need Is Still Coming

New Mexico began accepting psilocybin producer applications on August 17. The clinician permit has not opened, and the end of 2026 target looks unlikely.

Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster

Lilly paid up to $3.8 billion for a compound whose selling point is a two hour clinic visit. Session length, not efficacy, is now the axis that separates psychedelic programs.

Oregon Tracks Psilocybin Safety for Three Days. The New Data Found Problems at Three Months

A JAMA Network Open study followed 346 people through Oregon's licensed psilocybin program. The adverse events showed up long after the state stops looking.

The VA Just Started a Phase 3 Psilocybin Trial. The Control Group Gets Psilocybin Too

The VA began enrolling 240 veterans in a phase 3 psilocybin trial on August 3. There is no placebo arm, and that changes what the study can prove.

Psilocybin Sessions for PTSD Are Mostly Silent. The Argument About What to Call Them Is Not

A new analysis found psilocybin dosing sessions for PTSD are silent 78 percent of the time. Why the authors want the name changed, and who benefits if it is.

Cluster Headaches Have New Trial Data. Ketamine Clinics Should Be Paying Attention

Two 2024 randomized trials cut cluster headache attacks with pulse dose psilocybin. Where ketamine sits, why these patients overlap with yours, and the access gap.

Psychedelic Trials Are Going Intravenous. Ketamine Clinics Already Have That Room

A new trial of intravenous psilocin points to where psychedelic delivery is heading. Ketamine clinics already have the infusion rooms and titration skills it needs.

Three Psychedelic Companies Analysts Say Could Be Acquired Next

The Deal That Changed the Temperature Eli Lilly agreed in July to pay up to $3.8 billion for AtaiBeckley. That number reset expectations across psychedelic medicine. Analysts now openly discuss which company gets bought next. For clinic owners, the question matters more than it might appear. The companies being courted are building the treatments your […]